JONES, W., B.S. GONG, N. NOVORADOVSKAYA, D. LI, R. KUSKO, T.A. RICHMOND, D.J. JOHANN, H. BISGIN, S.M.E. SAHRAEIAN, P.R. BUSHEL, M. PIROOZNIA, K. WILKINS, M. CHIERICI, W.J. BAO, L.S. BASEHORE, A.B. LUCAS, D. BURGESS, D.J. BUTLER, S. CAWLEY, C.J. CHANG, G.C. CHEN, T. CHEN, Y.C. CHEN, D.J. CRAIG, A. DEL POZO, J. FOOX, M. FRANCESCATTO, YT FU, C. FURLANELLO, K. GIORDA, K.P. GRIST, M.J. GUAN, Y.Y. HAO, S. HAPPE, G. HARIANI, N. HASELEY, J. JASPER, G. JURMAN, D.P. KREIL, P. LABAJ, K. LAI, J.Y. LI, Q.Z. LI, Y.L. LI, Z.G. LI, Z.C. LIU, M.S. LOPEZ, K. MICLAUS, R. MILLER, V.K. MITTAL, M. MOHIYUDDIN, C. PABON-PENA, B.L. PARSONS, F.J. QIU, A. SCHERER, T.L. SHI, S. STIEGELMEYER, C. SUO, Nikola TOM, D. WANG, Z.N. WEN, L.H. WU, W.Z. XIAO, C. XU, Y. YU, J.Y. ZHANG, Y.F. ZHANG, Z.H. ZHANG, Y.T. ZHENG, C.E. MASON, J.C. WILLEY, W.D. TONG, L.M. SHI and J. XU. A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequency. GENOME BIOLOGY. LONDON: BIOMED CENTRAL LTD, 2021, vol. 22, No 1, p. 111-148. ISSN 1474-760X. Available from: https://dx.doi.org/10.1186/s13059-021-02316-z.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequency
Authors JONES, W., B.S. GONG, N. NOVORADOVSKAYA, D. LI, R. KUSKO, T.A. RICHMOND, D.J. JOHANN, H. BISGIN, S.M.E. SAHRAEIAN, P.R. BUSHEL, M. PIROOZNIA, K. WILKINS, M. CHIERICI, W.J. BAO, L.S. BASEHORE, A.B. LUCAS, D. BURGESS, D.J. BUTLER, S. CAWLEY, C.J. CHANG, G.C. CHEN, T. CHEN, Y.C. CHEN, D.J. CRAIG, A. DEL POZO, J. FOOX, M. FRANCESCATTO, YT FU, C. FURLANELLO, K. GIORDA, K.P. GRIST, M.J. GUAN, Y.Y. HAO, S. HAPPE, G. HARIANI, N. HASELEY, J. JASPER, G. JURMAN, D.P. KREIL, P. LABAJ, K. LAI, J.Y. LI, Q.Z. LI, Y.L. LI, Z.G. LI, Z.C. LIU, M.S. LOPEZ, K. MICLAUS, R. MILLER, V.K. MITTAL, M. MOHIYUDDIN, C. PABON-PENA, B.L. PARSONS, F.J. QIU, A. SCHERER, T.L. SHI, S. STIEGELMEYER, C. SUO, Nikola TOM (203 Czech Republic, belonging to the institution), D. WANG, Z.N. WEN, L.H. WU, W.Z. XIAO, C. XU, Y. YU, J.Y. ZHANG, Y.F. ZHANG, Z.H. ZHANG, Y.T. ZHENG, C.E. MASON, J.C. WILLEY, W.D. TONG, L.M. SHI and J. XU.
Edition GENOME BIOLOGY, LONDON, BIOMED CENTRAL LTD, 2021, 1474-760X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30101 Human genetics
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 17.906
RIV identification code RIV/00216224:14740/21:00120109
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1186/s13059-021-02316-z
UT WoS 000641654300003
Keywords in English COPY NUMBER VARIATIONS; SOMATIC MUTATIONS; QUALITY-CONTROL; INDEL DETECTION; READ ALIGNMENT; EXOME; ACCURATE; DISCOVERY; FRAMEWORK; DATABASE
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 18/5/2022 13:16.
Abstract
BackgroundOncopanel genomic testing, which identifies important somatic variants, is increasingly common in medical practice and especially in clinical trials. Currently, there is a paucity of reliable genomic reference samples having a suitably large number of pre-identified variants for properly assessing oncopanel assay analytical quality and performance. The FDA-led Sequencing and Quality Control Phase 2 (SEQC2) consortium analyze ten diverse cancer cell lines individually and their pool, termed Sample A, to develop a reference sample with suitably large numbers of coding positions with known (variant) positives and negatives for properly evaluating oncopanel analytical performance.ResultsIn reference Sample A, we identify more than 40,000 variants down to 1% allele frequency with more than 25,000 variants having less than 20% allele frequency with 1653 variants in COSMIC-related genes. This is 5-100x more than existing commercially available samples. We also identify an unprecedented number of negative positions in coding regions, allowing statistical rigor in assessing limit-of-detection, sensitivity, and precision. Over 300 loci are randomly selected and independently verified via droplet digital PCR with 100% concordance. Agilent normal reference Sample B can be admixed with Sample A to create new samples with a similar number of known variants at much lower allele frequency than what exists in Sample A natively, including known variants having allele frequency of 0.02%, a range suitable for assessing liquid biopsy panels.ConclusionThese new reference samples and their admixtures provide superior capability for performing oncopanel quality control, analytical accuracy, and validation for small to large oncopanels and liquid biopsy assays.
Links
LM2015064, research and development projectName: Český národní uzel Evropské infrastruktury pro translační medicínu (Acronym: EATRIS-ERIC-CZ)
Investor: Ministry of Education, Youth and Sports of the CR
LQ1601, research and development projectName: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
NV19-03-00091, research and development projectName: Komplexní prognostický a prediktivní panel pro pacienty s chronickou lymfocytární leukémií: nástroj sekvenování nové generace vhodný pro klinickou praxi i studium genetického pozadí průběhu choroby
Investor: Ministry of Health of the CR
PrintDisplayed: 6/9/2024 01:59